HIGHLIGHTS
- who: Marija Rozman and collaborators from the Department of Immunological and Molecular Diagnostics, University Hospital for Infectious Diseases Zagreb have published the research work: Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target Antigens, in the Journal: Pathogens 2022, 11, 864. of 27/07/2022
- what: This trial showed that the soluble gp350 monomer triggers immunogenicity, with the same result obtained with and without adjuvant addition.
- how: The gp350 vaccine with aluminum hydroxide as an adjuvant was tested in EBV-seronegative patients to prevent incidence of lymphoproliferative . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.